However, a notable divergence was observed in LOCRC NHW patients: JAK-STAT alterations were significantly less common among those receiving FOLFOX (7.5%) compared with those not treated with FOLFOX (13.3%, p = 0.0002) (Table 3b), suggesting a potential interaction between treatment exposure and age-associated tumor biology in this group. Here, SOAT1 is linked to neoplasm.